- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04447469
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Belém, Brazil, 66093-904
- Hospital Adventista de Belem
-
Fortaleza, Brazil, 60192-340
- IEP HGF - Instituto de Estudos e Pesquisas Clinicas do Ceará
-
São José, Brazil, 15090-000
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
-
São Paulo, Brazil, 01323-020
- Hospital Alemao Oswaldo Cruz
-
-
Bahia
-
Salvador, Bahia, Brazil, 40170-130
- Hospital Cardio Pulmonar
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30380-472
- Hospital Luxemburgo - Associação Mário Penna
-
-
Rio Grande Do Norte
-
Natal, Rio Grande Do Norte, Brazil, 59025-050
- CPCLIN - Centro de Pesquisas Clínicas
-
-
Rio Grande Do Sul
-
Lajeado, Rio Grande Do Sul, Brazil, 95900-000
- Hospital Bruno Born
-
-
Sao Paulo
-
Botucatu, Sao Paulo, Brazil, 18618-686
- UPECLIN - Unidade de Pesquisa Clínica
-
Campinas, Sao Paulo, Brazil, 13060-080
- IPECC - Instituto de Pesquisa Clínica de Campinas
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brazil, 65470-000
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
-
-
-
-
-
Santiago, Chile, 8380456
- Hospital Clínico Universidad de Chile
-
Santiago, Chile, 7550000
- Clinica Las Condes
-
-
-
-
-
Bellavista, Peru, 07011
- Hospital Nacional Alberto Sabogal Sologuren
-
Lima Cercado, Peru, 15082
- Essalud - Hospital de Emergencias Grau
-
San Martín De Porres, Peru, 15102
- Hospital Nacional Cayetano Heredia
-
San Miguel, Peru, 15088
- Clinica Providencia
-
-
-
-
-
Bloemfontein, South Africa, 9301
- Iatros International
-
Cape Town, South Africa, 7530
- Tiervlei Trial Center
-
George, South Africa, 6529
- TASK Eden
-
Pretoria, South Africa, 0181
- Into Research - Little Company of Mary Medical Center
-
Rustenburg, South Africa, 0299
- Limpopo Clinical Research Initiative
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7700
- University of Cape Town - Lung Institute
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Medical Center
-
San Diego, California, United States, 92110
- Sharp Health Care
-
-
Illinois
-
Chicago, Illinois, United States, 60644
- Affinity Health
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University School of Medicine
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Allina Health System
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- Mercy Clinic Hospitalists
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- University of Cincinnati
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, United States, 19010
- Bryn Mawr Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form. Consent must be performed per institutional regulations.
- Age of ≥ 18 years
- Positive SARS-CoV-2 (2019-nCoV) test within 14 days prior to randomization
- Hospitalized for SARS-CoV-2 (2019-nCoV)
- Bilateral pneumonia on chest x-ray or computed tomography
- Clinical laboratory results indicative of hyper-inflammation within 7 days prior to randomization
- Cohort 1: Receiving any form of non-invasive ventilation OR oxygenation to maintain SpO2 ≥ 92% and non-mechanically ventilated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation)
- Cohort 2: Recently ventilated with mechanical ventilation beginning within 48 hours prior to randomization
Key Exclusion Criteria:
- Onset of COVID-19 symptoms > 14 days prior to randomization
- Hospitalized > 7 days prior to randomization
- Need for invasive mechanical ventilation (Only for Cohort 1)
- Need for ECMO
- Serious prior or concomitant illness that in the opinion of the Investigator precludes the subject from enrolling in the trial
- Recent treatment with cell-depleting biological therapies (eg, anti-CD20) within 12 months, non-cell-depleting biological therapies (such as anti-tumor necrosis factor [TNF], anakinra, anti-IL-6 receptor [eg, tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer), treatment with alkylating agents within 12 weeks, treatment with cyclosporine A, azathioprine, cyclophosphamide, mycophenolate mofetil (MMF), or other immunosuppressant (except for corticosteroids) within 4 weeks prior to randomization. Medications that become standard of care for COVID-19 and/or receive emergency use authorization may be allowed after discussion with the medical monitor.
- If subject is receiving or has received hydroxychloroquine within 3 months prior to screening visit, a corrected QT interval by Federicia method (QTcF) on Screening electrocardiogram (ECG) ≥500ms is exclusionary. If subject has a pacemaker, this criterion does not apply.
- Enrolled in another investigational study of a medical intervention within 30 days prior to randomization. Participation in open label trials involving investigational treatments for COVID-19 may be allowed upon approval by the Sponsor.
- Life expectancy less than 48 hours, in the opinion of the Investigator
- Known human immunodeficiency virus infection (regardless of immunological status), known hepatitis B virus surface antigen positivity and/or anti-hepatitis C virus positivity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 10 mg/kg (Cohort 1)
Non-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
|
anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
Other Names:
|
ACTIVE_COMPARATOR: 6 mg/kg (Cohort 1)
Non-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
|
anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
Other Names:
|
PLACEBO_COMPARATOR: Placebo (Cohort 1)
Non-mechanically ventilated participants administered placebo as a single IV infusion
|
matching placebo
|
ACTIVE_COMPARATOR: 10 mg/kg (Cohort 2)
Mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
|
anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
Other Names:
|
ACTIVE_COMPARATOR: 6 mg/kg (Cohort 2)
Mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
|
anti-granulocyte-macrophage colony-stimulating factor receptor alpha (GM-CSF-Rα) monoclonal antibody (human isoform immunoglobulin G [IgG4])
Other Names:
|
PLACEBO_COMPARATOR: Placebo (Cohort 2)
Mechanically ventilated participants administered placebo as a single IV infusion
|
matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1: Proportion of subjects alive and free of mechanical ventilation at Day 29
Time Frame: Day 29
|
Mechanical ventilation is defined as invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Mechanical ventilation status will be evaluated based on the National Institute of Allergy and Infectious Diseases (NIAID) clinical outcome 8-point ordinal scale. Subjects whose clinical outcome has met a NIAID score of 2 will be considered as using mechanical ventilation. The NIAID is an 8-point ordinal scale of clinical outcomes: 1=death; 2=hospitalized, on invasive mechanical ventilation or ECMO; 3=hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5=hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID 19 related or otherwise); 6=hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7=not hospitalized, limitation on activities and/or requiring home oxygen; 8=not hospitalized, no limitations on activities. |
Day 29
|
Cohort 2: Mortality rate at Day 29
Time Frame: Day 29
|
Mortality rate is defined as the proportion of subjects who have died by Day 29.
|
Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohort 1: Mortality rate at Day 29
Time Frame: By Day 29
|
Mortality rate is defined as the proportion of participants who die.
|
By Day 29
|
Cohort 1: Ventilation-free survival by Day 29
Time Frame: By Day 29
|
Defined as time from randomization to ventilation or death; subjects still alive will be censored at Day 29.
|
By Day 29
|
Cohort 1: Overall survival by Day 29
Time Frame: Day 29
|
Defined as time from randomization to death; subjects still alive will be censored at Day 29.
|
Day 29
|
Cohort 2: Time to 1-point clinical improvement by Day 29
Time Frame: By Day 29
|
Defined as time from randomization to a 1-point improvement on the NIAID 8-point ordinal scale, or discharge from the hospital, whichever comes first.
Subjects who die before Day 29 will be censored at Day 30.
|
By Day 29
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KPL-301-C203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID
-
European Institute of OncologyFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; Azienda Ospedaliera... and other collaboratorsCompleted
-
Owlstone LtdCambridge University Hospitals NHS Foundation TrustCompleted
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Sultan Qaboos UniversityCompletedCOVID-19 | Non-CovidOman
-
Assiut UniversityRecruiting
-
Jilin UniversityUnknown
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Miami VA Healthcare SystemNot yet recruiting
Clinical Trials on mavrilimumab
-
MedImmune LLCMedImmune LtdCompletedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, Estonia, Hungary, Ukraine, Argentina, Chile, Germany, Serbia, Czech Republic, Colombia
-
MedImmune LLCMedImmune LtdCompletedA Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBulgaria, Poland, Russian Federation, Estonia, Hungary, Latvia, Lithuania, Romania, Ukraine, Czechia, Japan
-
MedImmune LLCTerminatedRheumatoid ArthritisBulgaria, Poland, Russian Federation, South Africa, Spain, United Kingdom, Estonia, Hungary, Ukraine, Argentina, Chile, Czechia, Israel, Slovakia, Greece, Germany, Serbia, Colombia, Mexico
-
MedImmune LLCCompletedHealthy VolunteersUnited Kingdom
-
Virginia Commonwealth UniversityKiniksa Pharmaceuticals, Ltd.CompletedCOVID-19 | Pneumonia | Sars-CoV2United States
-
The Cleveland ClinicKiniksa Pharmaceuticals, Ltd.CompletedPneumonia | SARS-CoV 2 | COVID 19United States
-
Ospedale San RaffaeleUnknownCovid-19 | Acute Respiratory Failure | ARDS, Human | Sars-CoV2 | Viral PneumoniaItaly
-
Kristin HudockKiniksa Pharmaceuticals, Ltd.UnknownPneumonia | SARS-CoV 2 | COVID 19United States
-
MedImmune LLCCompletedRheumatoid ArthritisRussian Federation, Spain, United Kingdom, Argentina, Hungary, Israel, Portugal, Slovakia, Greece, Serbia, Czech Republic, Colombia, France, Mexico
-
Kiniksa Pharmaceuticals, Ltd.CompletedGiant Cell ArteritisUnited States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain